NASDAQ:BIOS - BioScrip Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.92 +0.03 (+0.77 %)
(As of 12/19/2018 07:10 AM ET)
Previous Close$3.89
Today's Range$3.85 - $3.98
52-Week Range$2.31 - $4.14
Volume1.02 million shs
Average Volume1.38 million shs
Market Capitalization$498.08 million
P/E Ratio-8.91
Dividend YieldN/A
Beta0.55
BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:BIOS
Previous Symbol
CUSIP09069N10
Phone720-697-5200

Debt

Debt-to-Equity RatioN/A
Current Ratio1.79
Quick Ratio1.55

Price-To-Earnings

Trailing P/E Ratio-8.91
Forward P/E Ratio-11.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$817.19 million
Price / Sales0.61
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.66) per share
Price / Book-5.94

Profitability

EPS (Most Recent Fiscal Year)($0.44)
Net Income$-64,190,000.00
Net Margins-7.50%
Return on EquityN/A
Return on Assets-8.91%

Miscellaneous

Employees2,154
Outstanding Shares128,040,000
Market Cap$498.08 million
OptionableOptionable

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) released its quarterly earnings data on Tuesday, November, 6th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.02. The firm had revenue of $181 million for the quarter, compared to the consensus estimate of $171.35 million. The company's revenue for the quarter was down 8.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.12) EPS. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for BioScrip.

What guidance has BioScrip issued on next quarter's earnings?

BioScrip updated its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $-0.32--0.26 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-0.35. The company issued revenue guidance of $710-720 million, compared to the consensus revenue estimate of $697.28 million.

What price target have analysts set for BIOS?

5 brokerages have issued 12 month target prices for BioScrip's stock. Their predictions range from $3.25 to $10.00. On average, they expect BioScrip's share price to reach $5.15 in the next twelve months. This suggests a possible upside of 31.4% from the stock's current price. View Analyst Price Targets for BioScrip.

What is the consensus analysts' recommendation for BioScrip?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:
  • 1. According to Zacks Investment Research, "BioScrip concluded the second quarter on a mixed note. Although revenues beat the consensus mark, the massive year-over-year decline was a dampener. Additionally, quarterly loss was wider than the Zacks Consensus Estimate. According to the company, revenues were affected by the impact of higher core product mix, including contract changes with UnitedHealthcare, and the impact of implementing ASC 606 in 2018. Over the past six months, BioScrip has underperformed the industry.Nonetheless, we are encouraged by the company’s progress in the second quarter, courtesy of its new multi-faceted CORE plan to improve its financial position. The company also expects to earn core revenues at Home Solutions and witness continued core growth. The company also took certain rigorous steps to revitalize its sales force in the reported quarter. These developments should further drive business growth in 2018." (10/9/2018)
  • 2. Barrington Research analysts commented, "We continue to rate BIOS shares an OUTPERFORM and our price target is $4. We arrive at our price target by attaching a 14x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $550 million in net debt (including pfd stock) 12 months from now. Company Description BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post‐acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate‐site settings." (10/5/2018)

Has BioScrip been receiving favorable news coverage?

Media headlines about BIOS stock have been trending neutral this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioScrip earned a news impact score of 0.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 51)
  • Ms. Jody Kepler, Sr. VP, Chief Compliance Officer (Age 48)
  • Mr. John McMahon, Chief Accounting Officer, VP & Controller (Age 53)

Who are BioScrip's major shareholders?

BioScrip's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (12.02%), Venor Capital Management LP (11.31%), Gabelli Funds LLC (6.79%), BlackRock Inc. (5.95%), Vanguard Group Inc. (4.68%) and Vanguard Group Inc (4.68%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Michael G Bronfein and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Which institutional investors are selling BioScrip stock?

BIOS stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Gamco Investors INC. ET AL, Diamond Hill Capital Management Inc., FMR LLC, Bridgeway Capital Management Inc., Gilder Gagnon Howe & Co. LLC, Teton Advisors Inc. and Morgan Stanley. View Insider Buying and Selling for BioScrip.

Which institutional investors are buying BioScrip stock?

BIOS stock was bought by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Dimensional Fund Advisors LP, Perkins Capital Management Inc., Columbia Partners L.L.C. Investment Management, B. Riley Wealth Management Inc., Royce & Associates LP, Citadel Advisors LLC and Venor Capital Management LP. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $3.92.

How big of a company is BioScrip?

BioScrip has a market capitalization of $498.08 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.

What is BioScrip's official website?

The official website for BioScrip is http://www.bioscrip.com.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (NASDAQ BIOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel